| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC66308 | WAY-299775 Featured | potential leads for chaperone therapy for Gaucher disease |
|
| DC66309 | NFATc1-IN-1 Featured | NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research. |
|
| DC66310 | WAY-388798 Featured |
|
|
| DC66311 | BRD4 Inhibitor-24 Featured | BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively. |
|
| DC66312 | DB2313 HCl Featured | DB2313 is a first-in-class potent small-molecule inhibitor of PU.1. DB2313 disrupts the interaction of PU.1 with target gene promoters and leads to down-regulation of canonical PU.1 transcriptional targets. |
|
| DC66313 | WAY-301158 Featured | antitubercular activity; fungicidal activity; |
|
| DC66314 | WAY-310301 Featured | anti-inflammatory, COX inhibitory activities and ulcerogenic liability |
|
| DC66315 | WAY-326101 Featured | glucocerebrosidase activator; |
.gif)
|
| DC66316 | BMS-P5 HCl Featured | BMS-P5 is a Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor with pIC50 values in the range of 5-7.5. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression Targeting PAD4 may be beneficial for treatment of multiple myeloma. |
|
| DC66318 | WAY-301522 Featured |
|
|
| DC66319 | WYE-176249 Featured | VEGF inhibitor |
|
| DC66320 | WAY-301122 Featured | cytotoxity (targeted to DNA topoisomerase II); anti-cancer activity; fungicides; |
|
| DC66321 | WAY-328141 Featured | useful for the treatment of cystic fibrosis; modulating CFTR activity; altering the lifespan of a eukaryotic organism; |
|
| DC66322 | WAY-327512 Featured | activate TLR8-dependent NF-kB signaling |
|
| DC66323 | WAY-270252 Featured | IGF-1R/SRC inhibitor |
|
| DC66324 | WAY-358024 Featured | GSK-3b inhibitors; GSK-3b inhibitors; |
|
| DC66325 | CB2R PAM Featured | CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain. |
|
| DC66326 | Ropidoxuridine Featured | Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors. |
|
| DC66327 | Antibacterial agent 125 Featured | Antibacterial agent 125 is an antibacterial agent. Antibacterial agent 125 has a potent antimicrobial activity against clinically relevant Gram-positive pathogens with MIC50 values range from 0.25 - 8 μM. Antibacterial agent 125 can be used for the research of antimicrobial resistance. |
|
| DC66328 | OTS514 hydrochloride Featured | OTS514 hydrochloride is a highly potent TOPK inhibitor, which inhibits TOPK kinase activity with a median inhibitory concentration (IC50) value of 2.6 nM. OTS514 hydrochloride strongly suppresses the growth of TOPK-positive cancer cells. OTS514 hydrochloride induces cell cycle arrest and apoptosis. |
|
| DC66329 | Martinostat hydrochloride Featured | Martinostat (hydrochloride) is a inhibitor of HDAC that can be labeled with radionuclides for diagnostic applications. |
|
| DC66330 | Martinostat Featured | Martinostat is a histone deacetylase imaging agent. |
|
| DC66331 | NSC 31150 Featured |
|
|
| DC66332 | STM2120 Featured | STM2120 is a METTL3-METTL14 inhibitor with an IC50 of 64.5 μM. |
|
| DC66333 | ML 315 hydrochloride Featured | ML 315 hydrochloride is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research. |
|
| DC66334 | KA2507 monohydrochloride Featured | KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects. |
|
| DC66335 | ANO61 Featured | ANO61 is a dibenzyl formamide derivative, which exhibits an antiplatelet efficacy through modulation of thrombin-induced Ca2+ response with an IC50 of 47.7 μM. |
|
| DC66336 | BD1063 HCl Featured | BD1063 is a selective sigma receptor antagonist, with a reported binding affinity of Ki = 9 ± 1 nM for the sigma-1 receptor and more than 49 times selectivity over the sigma-2 receptor. Consistent with other reported sigma receptor antagonists, pretreating Swiss Webster mice with BD1063 significantly decreases the convulsivity and lethality of cocaine. In other animal studies, BD1063 blocks the effects of MDMA, and reduces alcohol intake in rodent models of alcoholism. |
|
| DC66337 | GLUT4 activator 2 Featured | GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation. |
|
| DC66338 | GW549390X Featured | GW549390X is a dual inhibitor of Fluc and VEGFR2 with IC50 of 0.26 μM and 1.2 μM, respectively. GW549390X can bind to the ATP pocket of FLuc through the aniline side chain and is an ATP-competitive inhibitor of Fluc. GW549390X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases, with potential implications for Fluc reporter assays. |
|
